期刊文献+

金雀异黄素对胶原诱导性大鼠成纤维样滑膜细胞分泌的血管新生相关因子的影响 被引量:5

Effect of genistein on the angiogenes is -related factors secreted by fibroblast-like synoviocytes from rats with collagen Ⅱ induced arthritis
原文传递
导出
摘要 目的观察金雀异黄素(genistein)对Ⅱ型胶原诱导性关节炎(CIA)大鼠关节成纤维样滑膜细胞(FLS)分泌的血管内皮生长因子(VEGF)及基质金属蛋白酶(MMP)-1、2、3、9的影响。方法采用Ⅱ型胶原和完全弗氏佐剂(CFA)建立CIA大鼠模型;每周进行一次关节炎指数(AI)评分;于造模第6周摄取关节X线片,选取大鼠关节进行关节滑膜组织病理检测;取出关节滑膜组织,用胶原酶消化法分离培养原代成纤维样滑膜细胞;流式法检测滑膜细胞血管细胞黏附分子(VCAM)-1的表达;在FLS培养中加入用不同浓度的金雀异黄素(100,200,400μmol/L),间接酶联免疫吸附试验(ELISA)法检测FLS培养上清中VEGF及MMP-1、2、3、9的表达。结果Ⅱ型胶原和CFA共同致敏后3d,大鼠开始出现关节肿胀,AI逐渐增高,于第3周时最明显,观察AI评分、关节X线以及关节滑膜组织病理发现,造模组与空白对照组比较差异有统计学意义。大鼠滑膜细胞培养至第4代,检测其VCAM-1的表达高达85.5%,提示所培养的细胞即为FLS。不同浓度的金雀异黄素(100,200,400μmol/L)和甲氨蝶呤(MTX,1mg/L)作用于FLS后,FLS培养上清中VEGF和MMP-1、2、3、9的分泌受到抑制,且抑制作用强度与药物的浓度有关。结论本实验使用Ⅱ型胶原和完全弗氏佐剂成功构建了CIA大鼠模型,用胶原酶消化法成功地分离并培养了原代大鼠成纤维样滑膜细胞。一定浓度的金雀异黄素能抑制CIA大鼠FLS分泌的VEGF和MMP-1、2、3、9,且抑制作用呈浓度依赖性。 Objective To investigate the effect of genistein (gen) on the secretion of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs-1, 2, 3, 9) by fibroblast-like synovioeytes (FLS) from rats with collagen induced arthritis (CIA). Methods The CIA was induced by collagen Ⅱ and complete Freund's adjuvant (CFA) into rats. The rats were scored based on the arthritis index(AI) once a week. At the sixth week, the X-ray of joints was taken. The synovial tissues from knee joints were examined pathologically. The primary fibroblast-like synoviocytes were separated from the synovial tissue by eollagenase digestion and cuhured. Then the expression of VCAM-1 was estimated by flow cytometry. After adding gen (100, 200, 400 μmol/L) at different concentrations into the FLS, VEGF and MMP-1, 2, 3, and 9 of the supernatants were tested by indirect ELISA. Results After 3 days of type Ⅱ collagen and CFA injec-tion, the rats started to catch arthrocele and their arthritis index increased gradually. The arthroeele was most remarkable at the 3rd week. The AI, X-ray and pathological examination indicated that the model group were significantly different from the control group. After the synoviocytes were cultured to the 4th generation, the expression of VCAM-1 was as high as about 85.5%. It showed that most synovioeytes were changed to fibroblast-like synoviocytes. Different concentrations of gen ( 100, 200, 400 μmol/L) added to FLS were compared and revealed that the VEGF and MMP-1, 2, 3, and 9 in the supernatants were suppressed evidently and in a dose-dependent manner. Conclusion The CIA model can be successfully constructed by collagen type Ⅱ and CFA; Tthe primary FLS of rats' joint can be separated and cultured well by collagenase digestion. Certain levels of gen can suppress the secretion of VEGF and MMP-1, 2, 3 and 9 by FLS. The affect is dose-dependent.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2010年第1期25-29,共5页 Chinese Journal of Rheumatology
基金 江苏省高校自然科学基础研究项目(07K.ID320245)
关键词 大鼠 Sprague—Dawley 关节炎 实验性 血管内皮生长因子A 基质金属蛋白酶类 Rats, Sprague-Dawley Arthritis, experimental Vascular endothelial growth factors A Matrix metalloproteinases
  • 相关文献

参考文献13

  • 1Fiedorczyk M, Klimiuk PA, Sierakowski S, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathogenesis of rheumatoid arthritis. Pol Merkur Lekarski, 2006, 20: 228.
  • 2Ravindranath MH, Muthugounder S, Presser N, et al. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol, 2004, 546: 121.
  • 3Kim MH. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. Cell Biochem, 2003, 89: 529.
  • 4Barrett JR. The science of soy: what do we really know? Environ Health Perspect, 2006, 114: 352.
  • 5Morales-Ducret J, Wayner E, Elices MJ, et al. Alpha4/betal integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-I in synovium and on fibroblast-like synoviocytes. Immunology, 1992, 149: 1424.
  • 6Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatic diseases. Curr Opin Rheumatol, 2005, 17: 293.
  • 7Rundhaug JE. Matrix metalloproteinases and angiogenesis. Cell Mol Med, 2005, 9: 267.
  • 8Giannelli G, Erriquez R, Iannone F, et al. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol, 2004, 22: 335.
  • 9Fiedorczyk M, Klimiuk PA, Sierakowski S, et al. Serum matrix metalloproteinases and tissue iuhibitors of metalloproteinases in patients with early rheumatoid arthritis. Rheumatology, 2006, 33: 1523.
  • 10Simons M. Integrative signaling in angiogenesis. Mol Cell Biochem, 2004, 264( 1/2): 99.

二级参考文献3

共引文献14

同被引文献45

  • 1朱松柏,吕永曼.金雀异黄素抗癌作用分子机制研究进展[J].华中医学杂志,2006,30(3):253-254. 被引量:11
  • 2Su SJ,Yeh TM,Chuang WJ,et al.The novel targets for anti-angiogenesis of genistein on human cancer cells[J].Biochem Pharmacol,2005,69(2):307-318.
  • 3Farina HG,Pomies M,Alonso DF,et al.Antitumor andanti-angiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer[J]. Oncol Rep,2006,16(4):885-891.
  • 4Takayanagi H,Lizuka H,Juji T,et al.Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis[J].Arthritis Rheum,2000,43(2):259-269.
  • 5Tolboom TC,Pieterman E,Laan WH,et al.Invasive properties of fibroblast-like synoviocytes:correlation with growth characteristics and expression of MMP-1,MMP-3 and MMP-10[J].Ann Rheum Dis,2002,61(11):975-980.
  • 6Veale DJ,Fearon U.Inhibition of angiogenic pathways in rheumatoid arthritis:potential for therapeutic targeting[J].Best Pract Res Clin Rheumatol,2006,20(5):941-947.
  • 7Jiang W,Xiang C,Cazacu S,et al.Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration[J].Neoplasia,2008,10(12):1335-1342.
  • 8D'Souza WN,Chang CF,Fischer AM,et al.The Erk2MAPK regulates CD8 T cell proliferation and survival[J].J Immunol,2008,181(11):7617-7629.
  • 9Allaire S, Wolfe F, Niu J, et al. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US [ J ]. Arthritis Rheum, 2008, 59:474-480.
  • 10Ando K, Mori K, R6dini F, et al. RANKL/RANK/ OPG: key therapeutic target in bone oncology [ J ]. Curr Drug Discov Technol, 2008, 5:263-268.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部